Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Q2 2025 highlights from Vaxcyte, Inc. (PCVX) 10-Q. The company reported consolidated total assets of $3,305,363 and a six-month net loss of $307,291 (YTD), including a Q2 net loss of $166,573. Cash and cash equivalents declined to $306,744 at June 30, 2025 from $387,878 at December 31, 2024. Short-term and long-term investments totaled $2,519,774 (fair value).
Operating results and cash flow: R&D expense rose to $194,179 in Q2 2025 (Q2 2024: $131,507) and G&A to $32,040 (Q2 2024: $21,474), driving total operating expenses of $226,219 for the quarter. Net loss per share was $(1.22) for Q2 and $(2.26) for the six months. Net cash used in operating activities was $287,440 for the six months.
- Shares outstanding: 129,816,472 at June 30, 2025.
- Manufacturing buildout: $196.3M capital expenditures (company-owned) and $94.3M facility buildout expenditures owned/controlled by Lonza (including CHF27M repurposing fee).
- Commitments: $484,543K non-cancelable purchase commitments to manufacturing partners; lease liabilities total $85,845K (discounted).